Business
Mesoblast scores US regulatory breakthrough – The Australian Financial Review
Mesoblast has scored a win in marketing its stem cell therapy drug in the US after a verdict was delivered about 7am AEST.
A US healthcare Oncologic Drugs Advisory Committee (ODAC) meeting has voted eight to two in favour of a Mesoblast drug to treat transplant rejections in children.
The verdict was delivered about 7am AEST after the US Food and Drug Administration’s (FDA) Advisory Committee majority voted the available clinical data supplied by Mesoblast support the efficacy of its Ryoncil drug in pediatric patients with acute-Graft Versus Host Disease (aGVHD).
The final decision on whether to approve Mesoblast’…
-
General16 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News23 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
Noosa News16 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General23 hours agoCrowe toasts talkback titan for platforming ‘voiceless’